Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Grows By 57.5%

Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the recipient of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 79,200 shares, an increase of 57.5% from the May 15th total of 50,300 shares. Currently, 0.2% of the shares of the company are short sold. Based on an average daily trading volume, of 42,800 shares, the short-interest ratio is currently 1.9 days.

Institutional Investors Weigh In On Entera Bio

A number of hedge funds have recently modified their holdings of the business. HighTower Advisors LLC raised its holdings in Entera Bio by 53.3% in the 1st quarter. HighTower Advisors LLC now owns 18,140 shares of the company's stock worth $31,000 after purchasing an additional 6,310 shares during the period. Northern Trust Corp bought a new position in shares of Entera Bio in the fourth quarter worth about $450,000. Parkman Healthcare Partners LLC lifted its position in shares of Entera Bio by 6.3% during the 1st quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company's stock valued at $747,000 after buying an additional 25,900 shares in the last quarter. Finally, Knoll Capital Management LLC grew its stake in shares of Entera Bio by 51.5% during the 4th quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company's stock valued at $12,470,000 after acquiring an additional 2,000,000 shares during the period. Institutional investors own 14.11% of the company's stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Entera Bio in a report on Tuesday, March 18th.

Entera Bio Stock Down 11.0%

Shares of Entera Bio stock traded down $0.23 during trading hours on Friday, reaching $1.86. 52,053 shares of the stock traded hands, compared to its average volume of 69,405. Entera Bio has a one year low of $1.41 and a one year high of $2.79. The firm has a market capitalization of $84.54 million, a price-to-earnings ratio of -7.15 and a beta of 1.47. The company has a 50 day moving average price of $2.00 and a 200 day moving average price of $2.07.

Entera Bio (NASDAQ:ENTX - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The business had revenue of $0.04 million during the quarter. Sell-side analysts anticipate that Entera Bio will post -0.28 earnings per share for the current year.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.